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Introduction {#sec005}
============

Cancer has being the leading cause of mortality worldwide and is therefore a major public health threat. Solid tumors account for most of human cancers \[[@pone.0166230.ref001]\]. Currently, curative surgical resection is still the optimal therapy for primary solid tumor. However, outcome may vary in patients with the same tumor after surgery. Thus, to precisely evaluate the therapeutic effect and prognosis of patients who suffer from cancer, feasible and effective biomarkers are urgently needed.

Numerous studies have shown that cancer metabolism is closely related to cancer cell survival owing to the sharing of common signaling molecules between these two pathways \[[@pone.0166230.ref002]--[@pone.0166230.ref004]\]. Cancer cells prefer to convert glucose to lactic acid as the main source of energy, regardless of oxygen availability, a phenomenon designated the Warburg effect or aerobic glycolysis \[[@pone.0166230.ref005]\]. Aerobic glycolysis generates less ATP than oxidative phosphorylation (OXPHOS), but can rapidly provide sufficient energy and biosynthetic precursors for cellular proliferation. Therefore aerobic glycolysis has been identified as the seventh hallmark of cancer \[[@pone.0166230.ref006]\]. Although the glycolysis rate can be regulated by a number of metabolic enzymes in the glycolytic pathway, most studies have suggested that glycolytic flux primarily relies on upregulation of glucose transporters and hexokinase (HK) \[[@pone.0166230.ref007], [@pone.0166230.ref008]\]. Specifically, HK2 has been suggested to contribute to the increased glycolysis by catalyzing the conversion from glucose to glucose-6-phosphate in the glycolytic pathway of cancer cells \[[@pone.0166230.ref009]\].

Recently, overexpression of HK2 has been reported in various solid tumors, including colorectal cancer \[[@pone.0166230.ref010]\], hepatocellular carcinoma \[[@pone.0166230.ref011]\], ovarian cancer \[[@pone.0166230.ref012]\], and pancreatic cancer \[[@pone.0166230.ref013]\], indicating that HK2 plays an important role in the development and progression of cancer. However, the prognostic value of HK2 was still controversial. Many studies have shown that overexpression of HK2 is associated with poor prognosis \[[@pone.0166230.ref014]--[@pone.0166230.ref016]\], whereas a few studies have demonstrated the opposite results \[[@pone.0166230.ref010]\].

Thus, in order to clarify the prognostic significance of HK2 as a metabolic marker in various solid tumors, we performed a meta-analysis on data collected systematically.

Methods {#sec006}
=======

Search Strategy {#sec007}
---------------

The PubMed, Embase, and Web of Science databases were used for a comprehensive literature search with the following terms and their combinations: "hexokinase-2 or HK2 or HK-2", "cancer or carcinoma or tumor or neoplasm", and "prognosis or prognostic or outcome or survival". The last search was conducted on September 28, 2016. Any potential studies were manually searched for in the references.

Inclusion and Exclusion Criteria {#sec008}
--------------------------------

Eligible studies met the following inclusion criteria: evaluation of patients with pathologically diagnosed solid tumors; the study contained sample size more than 20; published in English; studies aimed to explore the association between HK2 expression and prognosis; and studies with hazard ratios (HRs) and confidence intervals (CIs), which could be directly obtained or calculated with relevant data.

The exclusion criteria were as follows: studies of tumor cell lines, animal experiments, or non-solid tumors; published in a language other than English; duplicate reports and inappropriate article types, such as case reports, letters, conference papers, and reviews; studies without sufficient data for obtaining HRs and CIs.

Data Extraction and Quality Assessment {#sec009}
--------------------------------------

Data were extracted from the included studies by two authors (Yulin Liu and Liang Shi) independently, and a third author (Ke Wu) was responsible for reconciling disagreements. Extracted data included first author's name, publication year, country, tumor type, sample size, tumor stage, mean age, cut-off value, and outcome. The adopted indexes for outcomes included overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS)/relapse-free survival (RFS). The quality of the included studies was assessed using the Newcastle-Ottawa Scale (case-control studies) \[[@pone.0166230.ref017]\]. The score ranged from 0 to 9, and studies with scores of 6 or more were regarded as high quality.

Statistical Analysis {#sec010}
--------------------

HRs and their 95% CIs were used to assess the prognostic value of elevated HK2 expression in solid tumor. The reported statistical variables were extracted directly from the primary studies. If not given explicitly, variables were calculated using the Kaplan-Meier method or available data according to Tierney's method \[[@pone.0166230.ref018]\]. Heterogeneity analysis was performed by visual observation of forest plots with the *I*^2^ statistic and Chi-squared tests \[[@pone.0166230.ref019]\]. *I*^2^ \> 50% and/or *p* \< 0.05 was considered representative of obviously heterogeneity, and a random effect model was applied to pool the HRs and their CIs. Otherwise, a fixed effect model was applied. Pooled HRs of greater than 1 represented poor prognosis of elevated HK2 expression, and results with *p* values of less than 0.05 were considered statistically significant. Subgroup analysis was further performed for interpretation of identified heterogeneity. Additionally, the consistency of pooled outcomes was examined with sensitivity analysis. Publication bias was investigated using funnel plots with Egger's test and Begg's test, and results with *p* values of less than 0.05 were considered to be indicative of significant bias. Stata 12.0 software was used for all statistical analyses in this meta-analysis.

Results {#sec011}
=======

Eligible Studies {#sec012}
----------------

According to our defined searching strategy, a total of 951 references were identified after an initial search. After screening by titles and abstracts, 876studies were excluded on account of duplicated data, irrelevant subject, inappropriate article type, and inappropriate study type (i.e., cell and animal experiments). The 75 remaining studies for the association of HK2 overexpression with cancer prognosis were evaluated by reading the full text. Finally, 21studies consisting of 2532 cases were evaluated in this meta-analysis ([Fig 1](#pone.0166230.g001){ref-type="fig"}).

![Flow diagram shows search strategy.](pone.0166230.g001){#pone.0166230.g001}

Characteristics of Included Studies {#sec013}
-----------------------------------

The main characteristics of the included studies are shown in [Table 1](#pone.0166230.t001){ref-type="table"}. Twenty-one eligible studies from China, Japan, Korea, the United States of America, Canada, and Germany included patients who had been diagnosed with a variety of solid tumors, such as hepatocellular carcinoma, gastric cancer, colorectal cancer and pancreatic cancer. HK2 protein and mRNA expression in tumor tissues were detected in 18 and three studies, respectively. 18 studies provided data on OS, which including hepatocellular carcinoma (n = 6), gastric cancer (n = 3), colorectal cancer (n = 2), pancreatic cancer (n = 2) and others (n = 5). Eight studies provided data on PFS/DFS/RFS. HRs were directly extracted from 14 studies and calculated with available data or survival curves from the other seven studies. The cut-off values for positive expression of HK2 varied in these studies. In quality assessment, all of the included studies had scores ranging from 6 to 9, indicating that they were of high quality.

10.1371/journal.pone.0166230.t001

###### The main characteristics of the included studies in the meta-analysis.

![](pone.0166230.t001){#pone.0166230.t001g}

  First author                              Year   Country   Tumor type   Sample size   Stage    Method   Mean age     Cut-off value    Analysis          Outcome   NOS
  ----------------------------------------- ------ --------- ------------ ------------- -------- -------- ------------ ---------------- ----------------- --------- -----
  **Zhang \[[@pone.0166230.ref020]\]**      2016   China     HCC          155           I-IV     IHC      NR           CS               univariate        OS        7
  **Guo \[[@pone.0166230.ref021]\]**        2015   China     HCC          120           I-IV     RT-PCR   NR           NR               survival curves   OS        7
  **Gong \[[@pone.0166230.ref022]\]**       2012   China     HCC          97            I-IV     RT-PCR   NR           0.39%            survival curve    OS        8
  **Kwee \[[@pone.0166230.ref023]\]**       2012   America   HCC          157           I-IV     IHC      NR           CS               multivariate      OS        9
  **Peng \[[@pone.0166230.ref014]\]**       2008   China     HCC          203           I-IV     RT-PCR   54.9         ratio ≥1.5       survival curve    OS        8
  **Paudyal \[[@pone.0166230.ref024]\]**    2008   Japan     HCC          31            I-IV     IHC      NR           CS               multivariate      OS        8
  **Hur \[[@pone.0166230.ref025]\]**        2013   Korea     GC           152           I-IV     IHC      55.8±13.6    staining≥30%     univariate        OS/DFS    7
  **Qiu \[[@pone.0166230.ref016]\]**        2011   China     GC           188           I-IV     IHC      57           NR               multivariate      OS        8
  **Rho \[[@pone.0166230.ref026]\]**        2007   Korea     GC           257           I-IV     IHC      54.6         staining≥10%     multivariate      OS        9
  **Katagiri \[[@pone.0166230.ref027]\]**   2016   Japan     CRC          195           I-IV     IHC      64.5         staining≥10%     multivariate      OS        8
  **Ho \[[@pone.0166230.ref028]\]**         2016   Canada    CRC          60            I-IV     IF       NR           F-Score ≥ 24.7   univariate        OS/PFS    7
  **Hamabe \[[@pone.0166230.ref010]\]**     2014   Japan     CRC          104           I-IV     IHC      NR           CS               survival curve    RFS       8
  **Ogawa \[[@pone.0166230.ref013]\]**      2015   Japan     PC           36            I- III   IHC      70           CS               multivariate      OS/RFS    7
  **Lyshchik \[[@pone.0166230.ref029]\]**   2007   Japan     PC           74            I-IV     IHC      63.5 ± 9.2   index≥3          survival curve    OS        8
  **Sato \[[@pone.0166230.ref030]\]**       2013   Japan     BC           118           I- III   IHC      57           staining≥10%     survival curve    DFS       7
  **Palmieri \[[@pone.0166230.ref031]\]**   2009   Germany   BC           123           NR       IHC      51           NR               multivariate      OS        8
  **Zhang \[[@pone.0166230.ref032]\]**      2016   China     NPC          140           I-IV     IHC      48           index≥3          multivariate      OS/PFS    9
  **Huang \[[@pone.0166230.ref033]\]**      2015   China     CCA          132           I-IV     IHC      51           staining≥25%     multivariate      PFS       8
  **Suh\[[@pone.0166230.ref012]\]**         2014   Korea     EOC          111           I-IV     IHC      NR           CS               multivariate      OS/PFS    9
  **Tsukada \[[@pone.0166230.ref034]\]**    2012   Japan     ULMS         23            I        IHC      51.5         CS               multivariate      OS        8
  **Wolf \[[@pone.0166230.ref015]\]**       2011   Canada    GBM          56            NR       IHC      NR           NR               multivariate      OS        7

HCC: hepatocellular carcinoma; GC: gastric cancer; CRC: colorectal cancer; PC: pancreatic cancer; BC: breast cancer; NPS: nasopharyngeal carcinoma; CCA: cervical carcinoma; EOC: epithelial ovarian carcinoma; ULMS: uterine leiomyosarcoma; GBM: glioblastoma multiforme; IHC: immunohistochemistry; RT-PCR: reverse transcription-polymerase chain reaction; IF: immunofluorescence; NR: not reported; CS: complex score combining intensity and percentage of HK2 expression.

Correlation of HK2 Expression with OS and Subgroup Analysis {#sec014}
-----------------------------------------------------------

The combined analysis of 18 studies showed that elevated HK2 expression was associated with worse OS (pooled HR = 1.90, 95% CI = 1.51--2.38, *p* \< 0.001) ([Fig 2](#pone.0166230.g002){ref-type="fig"}). Owing to moderate heterogeneity (*I*^*2*^ = 55.4%, *p* = 0.002), a random effect model was used to pool HRs.

![Forest plots to assess the effect of elevated HK2 expression on OS in patients with various solid tumors.](pone.0166230.g002){#pone.0166230.g002}

In order to identify the possible sources of heterogeneity across these studies, subgroup analysis was performed according to patients' ethnicity, tumor type, detection method, and analysis type ([Table 2](#pone.0166230.t002){ref-type="table"}). Subgroup analysis by patient ethnicity showed that HK2 overexpression was significantly associated with worse OS in Asian patients (pooled HR = 1.86, 95% CI = 1.39--2.49, *p* \< 0.001) and Caucasian patients (pooled HR = 1.97, 95% CI = 1.47--2.63, *p* \< 0.001). The negative effect of HK2 overexpression on OS was demonstrated in patients with hepatocellular carcinoma (pooled HR = 2.06, 95% CI = 1.67--2.54, *p* \< 0.001), gastric cancer (pooled HR = 1.72, 95% CI = 1.09--2.71, *p* = 0.020), colorectal cancer (pooled HR = 2.89, 95% CI = 1.62--5.16, *p* \< 0.001) and others (pooled HR = 2.15, 95% CI = 1.44--3.21, *p* \< 0.001), but not with pancreatic cancer (pooled HR = 1.13, 95% CI = 0.28--4.66, *p* = 0.864). In subgroup analysis based on detection method, overexpression of HK2 could significantly indicate poor outcome in patients with solid tumor (IHC: pooled HR = 1.85, 95% CI = 1.37--2.49, *p* \< 0.001; RT-PCR: pooled HR = 2.00, 95% CI = 1.51--2.65, *p* \< 0.001). Subgroup analysis by the type of analysis suggested that elevated HK2 expression was significantly associated with shorter OS using either univariate analysis (pooled HR = 1.72, 95% CI = 1.13--2.61, *p* = 0.011) or multivariate analysis (pooled HR = 1.99, 95% CI = 1.60--2.46, *p* \< 0.001).

10.1371/journal.pone.0166230.t002

###### Pooled HRs for OS according to subgroup analysis.

![](pone.0166230.t002){#pone.0166230.t002g}

  Subgroup                No. of patients   No. of studies   Random-effect model   Heterogeneity          
  ----------------------- ----------------- ---------------- --------------------- --------------- ------ ----------
  **Overall survival**    2178              18               1.90 (1.51, 2.38)     \< 0.001        55.4   0.002
  **Ethnicity**                                                                                           
      Asian               1782              14               1.86 (1.39, 2.49)     \< 0.001        63.4   0.001
      Caucasian           396               4                1.97 (1.47, 2.63)     \< 0.001        0      0.541
  **Tumor type**                                                                                          
      HCC                 763               6                2.06 (1.67, 2.54)     \< 0.001        0      0.767
      GC                  597               3                1.72 (1.09, 2.71)     0.020           52.1   0.124
      CRC                 255               2                2.89 (1.62, 5.16)     \< 0.001        0      0.731
      PC                  110               2                1.13 (0.28, 4.66)     **0.864**       81.7   0.019
      Others              453               5                2.15 (1.44, 3.21)     \< 0.001        17.6   0.303
  **Detection method**                                                                                    
      IHC                 1698              14               1.85 (1.37, 2.49)     \< 0.001        63.9   0.001
      RT-PCR              420               3                2.00 (1.51, 2.65)     \< 0.001        0      0.992
      IF                  60                1                3.37 (1.17, 9.74)     0.024           \-     \-
  **Analysis type**                                                                                       
      Multivariate        1317              11               1.99 (1.60, 2.46)     \< 0.001        4.3    0.402
      Univariate          861               7                1.72 (1.13, 2.61)     0.011           77.3   \< 0.001
  **Lyshchik\'s study**                                                                                   
      Yes                 2178              18               1.90 (1.51, 2.38)     \< 0.001        55.4   0.002
      No                  2104              17               2.00 (1.73, 2.32)     \< 0.001        0      0.475

Correlation of HK2 Expression with PFS/DFS/RFS {#sec015}
----------------------------------------------

Eight eligible studies were adopted to pool HRs for PFS/DFS/RFS. Without obvious statistical heterogeneity (*I*^*2*^ = 0.0%, *p* = 0.790), a fixed effect model was used to pool HRs. The results showed that elevated HK2 expression was associated with negative outcome in patients with solid tumor (pooled HR = 2.55, 95% CI = 1.89--3.45, *p* \< 0.001) ([Fig 3](#pone.0166230.g003){ref-type="fig"}). Additionally, data were analyzed based on PFS, DFS, and RFS. Patients with elevated HK2 expression had a significantly shorter PFS (pooled HR = 2.91, 95% CI = 2.02--4.22, *p* \< 0.001). Despite the lack of significant difference, a similar trend was observed for DFS (pooled HR = 1.89, 95% CI = 0.94--3.83, *p* = 0.074) and RFS (pooled HR = 2.02, 95% CI = 0.93--4.38, *p* = 0.076).

![Forest plots to assess the effect of elevated HK2 expression on PFS/DFS/RFS.](pone.0166230.g003){#pone.0166230.g003}

Sensitivity Analysis {#sec016}
--------------------

Sensitivity analysis was performed by sequentially omitting individual studies with a fixed-effect model ([Fig 4](#pone.0166230.g004){ref-type="fig"}). No studies were found to obviously impact the result pattern. Interestingly, one study by Lyshchik et al \[[@pone.0166230.ref022]\] contributed the most to the observed heterogeneity. After deletion of this study, the observed heterogeneity dramatically decreased (*I*^*2*^ = 55.4%, *p* = 0.002 versus *I*^*2*^ = 0.0%, *p* = 0.475). However, the association between HK2 expression and OS was not altered when this study was included (pooled HR = 1.90, 95% CI = 1.51--2.38, *p* \< 0.001) or excluded (pooled HR = 2.00, 95% CI = 1.73--2.32, *p* \< 0.001).

![Sensitivity analysis of the evaluation on the relationship between HK2 expression and OS.](pone.0166230.g004){#pone.0166230.g004}

Publication Bias {#sec017}
----------------

Publication bias was not found by visual assessment of funnel plots ([Fig 5](#pone.0166230.g005){ref-type="fig"}), and this analysis was confirmed by Begg's test (*p* = 0.325) and Egger's test (*p* = 0.441). Because fewer than 10 eligible studies were used to pool HRs for PFS/DFS/RFS, funnel plots, Begg's tests, and Egger's tests were not performed and publication bias was not assessed in these analyses.

![Funnel plots to evaluate publication bias of included studies for OS.](pone.0166230.g005){#pone.0166230.g005}

Discussion {#sec018}
==========

In the past several decades, aerobic glycolysis has attracted increasing attention as a hallmark of cancer cells. Metabolic reprogramming furnishes cancer cells with sufficient precursor substances for rapid cell proliferation \[[@pone.0166230.ref035], [@pone.0166230.ref036]\]. As a key irreversible step in the glycolytic pathway, the phosphorylation of glucose catalyzed by HK plays a pivotal role in aerobic glycolysis. Meanwhile, HK is involved in the initiation and progression of tumor; in particular, HK2 is a critical component integrating cell viability and energy production pathways \[[@pone.0166230.ref021], [@pone.0166230.ref037]\]. The pro-survival effect of HK2 is achieved mainly through the following three mechanisms: (1) upregulation of HK2 facilitates the generation of biosynthetic precursors for cellular proliferation by increasing glycolysis rate \[[@pone.0166230.ref038]\]; (2) overexpression of HK2 could increase NADPH levels in the cytoplasm through the pentose phosphate pathway, contributing to protection of cells from oxidative damage \[[@pone.0166230.ref039]\]; and (3) HK2 can bind to mitochondria and preserve mitochondrial integrity in order to block mitochondrial death pathways \[[@pone.0166230.ref040]\]. Therefore, elevated expression of HK2 is critical for promoting tumor progression.

Accumulating evidence has revealed that elevated HK2 expression is associated with not only the development and progression of tumor \[[@pone.0166230.ref037], [@pone.0166230.ref041]\], but also with an unfavorable prognosis \[[@pone.0166230.ref023]\]. The overexpression of HK2 was positively correlated with tumor stage, differentiation and lymph node metastasis, as well as with a reduction in survival \[[@pone.0166230.ref010], [@pone.0166230.ref016], [@pone.0166230.ref021], [@pone.0166230.ref032]\].To the best of our knowledge, the present study is the first meta-analysis systematically exploring the prognostic value of elevated HK2 expression in solid tumor. In brief, our meta-analysis provided strong support that elevated HK2 expression was a significant independent indicator of poor outcome based on pooled HRs estimates. HK2 was associated with shorter OS in hepatocellular carcinoma, gastric cancer and colorectal cancer. The adverse prognostic effect of HK2 overexpression was virtually unaffected by ethnic background, analysis type and detection method. Moreover, patients with elevated HK2 expression had a significantly shorter PFS. Besides as an independent indicator of poor prognosis, combination of the expression of HK2 and other biomarkers could hold potent prognostic value in patients with solid tumor. In pancreatic cancer, although the positive expression of HK2 exhibited borderline significant prognostic value for OS, the combination of elevated expression of HK2 and PKM2 was found to be significant (P\<0.05) \[[@pone.0166230.ref013]\]. Hamabe et al. reported that the combined evaluation of positive HK2 and negative phosphorylated pyruvate dehydrogenase (p-PDH) was associated with reduced RFS in stage II and III patients with CRC \[[@pone.0166230.ref010]\].\[[@pone.0166230.ref029]\]

Interestingly, we also found HK2 failed to predict the outcome of patients with pancreatic cancer. This discrepancy may be partly attributed to the small sample size in the individual studies \[[@pone.0166230.ref013], [@pone.0166230.ref029]\]. In addition, data from univariate analysis were adopted to estimate the prognostic role of HK2 expression in the study by Lyshchik et al \[[@pone.0166230.ref029]\], allowing us to ignore the effects of clinicopathological factors on the prediction efficacy of HK2. Sensitivity analysis revealed that the study by Lyshchik et al was the main source of heterogeneity. After deletion of this study, the observed heterogeneity completely disappeared. Finally, considering that pancreatic cancer remains a lather disease in spite of improvement in early diagnosis, curative surgical resection, and adjuvant therapies, multidisciplinary treatment is required for a complete cure \[[@pone.0166230.ref042]\]. Preoperative treatment have an effect on immunohistochemical staining patterns, which may impair the predictive efficacy of HK2 on outcome in tumor.

And yet for all that, as a key regulator of glycolysis, the expression of HK2 is likely significant for the progression and prognosis of pancreatic cancer. The dense desmoplastic region surrounding pancreatic cancer cells inhibits neovascularization, leading to the deficiency of oxygen and nutrients in tumor tissue \[[@pone.0166230.ref043], [@pone.0166230.ref044]\]. Under such stressful microenvironment, cancer cells undergo a shift in cellular metabolism from oxidative phosphorylation to glycolysis \[[@pone.0166230.ref045]\], as a hallmark of cancer cells. Therefore, more studies designed rationally are required to confirm that elevated HK2 expression is associated with unfavorable outcome in patients with pancreatic cancer.

In spite of the strong results of our study, there were still several limitations to our meta-analysis. First, although the study by Lyshchik et al was identified as the main source of heterogeneity, specific clinical elements that contributed to the heterogeneity were not explicit. Second, due to the use of various cut-off values in the included studies, the utility of HK2 as a prognostic biomarker was impaired in patients with solid tumor. Accordingly, it may be necessary to standardize detection methods and cut-off values. Third, because multiple factors affect prognosis, we preferred to include studies in which multivariate analysis had been performed; however, eight studies with univariate analysis only were still included for a comprehensive analysis. In general, multivariate analysis is more efficient and precise when there are multiple interacting variables in one experiment \[[@pone.0166230.ref046]\]. Subgroup analysis indicated that multivariate analysis also yielded more stable results. Finally, the approach for obtaining essential data to pool HRs could be a potential source of heterogeneity. The pooled HRs extracted directly from the primary studies seemed to be more reliable than those calculated with survival curves or available data. Although subgroup analysis by tumor type was conducted, the impact of HK2 on prognosis was lost in some specific forms of cancer. Hence, it is essential for more studies to enroll patients with specific forms of cancer.

In conclusion, our meta-analysis suggested that HK2 could act as an independent prognostic factor for patients with solid tumor, but the association between HK2 and prognosis varies according to cancer type. Based on the above-mentioned limitations, this conclusion should be further confirmed by additional clinical studies with larger sample sizes.
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###### Forest plot to assess the effect of elevated HK2 expression on OS after omitting Lyshchik's study.
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